The list gets longer: Merck, Allergan, Novartis issue 2020 drug price hikes — report
The price train continues chugging in one direction.
On Friday, a trio of drugmakers — US-based Merck, Ireland-headquartered Allergan and Swiss drugmaker Novartis — issued a round of hikes on more than 100 medicines, vaulting the total number of price raises on 445 drugs in 2020, Reuters reported, citing healthcare research firm 3 Axis Advisors.
These spikes follow those by a cadre of drugmakers including GSK, Pfizer, Gilead, Bristol-Myers, Biogen, Lilly, and Teva earlier in the first week of 2020. In most cases, the sticker price increases have been limited to the mid-single-digit percentages. As the spotlight on drug pricing intensified, with patients, policymakers, and politicians decrying the magnitude and frequency of hikes, a raft of drugmakers — led by Allergan CEO Brent Saunders — previously pledged to not raise their prices by more than 10% annually.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.